Roche gets third pivotal win with MS drug, but liver signal could be a problemnews2026-03-02T15:25:33+00:00March 2nd, 2026|Endpoints News|
FDA lifts hold on second Intellia Phase 3 gene editing trialnews2026-03-02T15:23:14+00:00March 2nd, 2026|Endpoints News|
Candid to go public via reverse merger with Rallybionews2026-03-02T14:28:52+00:00March 2nd, 2026|Endpoints News|
Bavarian Nordic CEO Paul Chaplin exits, months after failed $3B takeovernews2026-03-02T14:09:32+00:00March 2nd, 2026|Endpoints News|
UniQure says FDA prefers randomized trial for Huntington’s treatmentnews2026-03-02T12:35:27+00:00March 2nd, 2026|Endpoints News|
China obesity biotech QL Biopharm gets $72M, including support from OrbiMednews2026-03-02T12:14:18+00:00March 2nd, 2026|Endpoints News|
Novartis’ Rhapsido shows promise in Phase 2 food allergy datanews2026-02-28T19:45:09+00:00February 28th, 2026|Endpoints News|
Merck looks to expand Welireg label following combo readouts with Keytruda, Lenvimanews2026-02-28T15:00:54+00:00February 28th, 2026|Endpoints News|
GLP-1 news galore; Top 100 venture investors; Doug Ingram to step down; and morenews2026-02-28T11:00:37+00:00February 28th, 2026|Endpoints News|
Ascendis wins FDA approval for achondroplasia drug, waits on EU actionnews2026-02-27T22:52:42+00:00February 27th, 2026|Endpoints News|
